Venus Remedies Limited share price

Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management. It also provides analgesic, analgesic and antipyretic, antibiotic, antidiabetic anticoagulant, antiemetic, antiviral, cardiac, cardiovascular, CNS, disinfectant and antiseptic, gastro therapy, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, mucolytic, muscle relaxant, neurology, respiratory, stress reliver, urology, vitamins, nutrients, miner…Read more

Website NSE BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: VENUSREMISIN INE411B01019

16 Oct 2026, 3:29 PM IST₹1,650.70▲ 78.50 (4.99%)

Market Cap₹ 2,209 Cr.
Current Price₹ 1,650.70
High / Low₹ 2,044 / 432
Stock P/E19.0
Book Value₹ 497
Dividend Yield0.64 %
ROCE19.4 %
ROE16.80 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 86.91
Price / Book3.32
OPM14.5 %
Debt / Equity0.02
Sales growth (5Y)7.0 %
Profit growth (5Y)10.7 %
Promoter holding47.2 %
EV / EBITDA12.7
Beta0.33
All-time high₹ 2,044

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
VENUSREM	+7.53%	-7.70%	+58.79%	+115.47%	+261.68%	+82.15%	+66.89%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Venus Remedies Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹2,209 crore.
It trades at 19.0 times its last 12 months' earnings and 3.3 times book value.
Revenue grew 7.0% a year over the last 5 years, profit 10.7% a year.
Return on equity was 16.8% and return on capital employed 19.4% in the latest year.
Debt was 0.02 times shareholders' equity.
The share price is 19.3% below its 52-week high and up 261.7% over one year.
Promoters and insiders hold about 47.2%; institutions about 1.4%.

Pros

Company is almost debt-free (debt is 0.02 times equity).
Latest quarter (Jun 2026): sales up 36% and profit up 139% from a year ago.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Venus Remedies Limited

Employees: 1,472
Head office: Panchkula

Peer comparison

Company	Market cap (₹ Cr)	P/E	P/B	ROE	OPM	Sales CAGR	Div. yield
Venus Remedies LimitedVENUSREM	2,209	19.0	3.32	16.8%	14.5%	+9.9%	0.64%
Sun Pharmaceutical Industries LimitedSUNPHARMA	4,21,995	34.9	5.05	14.7%	23.4%	+10.4%	0.91%
Divi's Laboratories LimitedDIVISLAB	2,42,758	83.0	14.48	16.2%	28.4%	+11.0%	0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM	1,73,406	72.8	18.39	27.1%	25.0%	+13.3%	0.83%
Zydus Lifesciences LimitedZYDUSLIFE	1,12,020	25.0	4.17	19.7%	21.7%	+16.5%	0.09%
Cipla LimitedCIPLA	1,07,051	31.8	3.11	11.8%	17.5%	+7.2%	0.98%
Dr. Reddy's Laboratories LimitedDRREDDY	1,02,707	31.0	2.68	12.1%	14.9%	+11.0%	0.66%
Abbott India LimitedABBOTINDIA	55,609	34.4	11.65	34.5%	26.3%	+9.0%	2.01%
Ajanta Pharma LimitedAJANTPHARM	41,599	36.7	9.19	25.4%	24.5%	+13.4%	1.91%

Companies in the same industry (Drug Manufacturers - Specialty & Generic). Tap a heading to sort. Sorting is a way to explore data, not a recommendation.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	95	168	143	195	109	167	177	195	132	193	180	259	179
YOY Sales Growth %		19.89%	22.69%	25.39%	14.15%	-0.16%	23.32%	-0.10%	21.44%	15.11%	1.92%	33.05%	35.60%
	85	150	131	176	97	163	159	166	122	162	143	196	145
Material Cost %	50%	58%	62%	62%	53%	64%	62%	53%	56%	56%	48%	46%	47%
Employee Cost %	17%	11%	12%	10%	17%	13%	11%	11%	15%	12%	12%	9%	13%
Other Expenses %	22%	20%	17%	18%	20%	20%	16%	21%	21%	16%	20%	20%	21%
Operating Profit	10	18	12	19	11	5	18	29	10	31	38	63	34
OPM %	11%	11%	8%	10%	10%	3%	10%	15%	8%	16%	21%	24%	19%
	2	3	2	4	2	11	2	7	9	2	3	5	3
Exceptional items							10
Interest	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	8	6	7	6	6	6	5	5	6	6	7	7	7
Profit before tax	5	14	8	17	7	9	25	31	13	26	33	62	30
	77%	31%	12%	40%	82%	61%	21%	23%	24%	24%	24%	23%	24%
Current tax	3	4	-0	5	3	4	7	5	4	6	8	14	8
Deferred tax	0	1	1	2	3	2	-2	2	-1	-0	-0	-0	-1
	1	10	7	11	1	4	20	21	10	20	26	47	23
Profit to shareholders				11
YOY Profit Growth %		86.49%	108.21%	-5.02%	3.39%	-64.64%	186.13%	99.90%	686.89%	472.69%	30.51%	126.14%	139.27%
EPS in Rs	0.88	7.44	5.13	7.86	0.92	2.63	14.66	15.71	7.18	15.06	19.14	35.53	17.18
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	99	170	131	175	106	167	173	194	132	193	180	259	179
YOY Sales Growth %	-36.34%	36.42%	19.90%	17.93%	7.33%	-1.86%	31.48%	10.78%	24.55%	15.35%	4.29%	33.48%	35.61%
	85	157	118	154	92	157	150	171	119	163	143	200	142
Material Cost %	55%	65%	63%	60%	54%	66%	61%	53%	56%	56%	48%	46%	47%
Employee Cost %	14%	10%	12%	10%	15%	12%	10%	10%	15%	11%	11%	9%	13%
Other Expenses %	18%	18%	15%	18%	17%	17%	16%	26%	20%	17%	21%	22%	20%
Operating Profit	13	13	13	21	14	10	23	23	13	30	37	59	37
OPM %	14%	8%	10%	12%	13%	6%	13%	12%	10%	15%	20%	23%	20%
	2	3	2	4	2	11	2	7	8	2	2	5	3
Exceptional items							10
Depreciation	7	6	6	6	6	6	5	4	6	6	6	7	7
Profit before tax	8	10	9	19	10	15	29	25	15	26	33	58	33
	47%	45%	10%	36%	56%	37%	18%	29%	20%	25%	24%	25%	22%
Current tax	3	4	-0	5	3	4	7	5	4	6	8	14	8
Deferred tax	0	1	1	2	3	2	-2	2	-1	-0	-0	-0	-1
	4	5	8	13	4	9	24	15	12	19	25	43	26
YOY Profit Growth %	-60.87%	-29.50%	213.79%	65.98%	2.53%	69.91%	194.02%	18.18%	162.70%	107.78%	3.49%	193.91%	118.39%
EPS in Rs	3.25	4.07	6.13	9.36	3.33	6.92	18.02	11.07	8.75	14.40	18.64	32.51	19.10
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	372	372	341	548	599	556	601	648	770	811
YOY Sales Growth %			-8.31%	60.52%	9.22%	-7.21%	8.27%	7.72%	18.79%
	333	333	301	494	537	495	542	584	622	645
Material Cost %	55%	55%	51%	62%	64%	60%	59%	58%	50%	49%
Employee Cost %	11%	11%	13%	8%	9%	11%	12%	12%	12%	11%
Other Expenses %	24%	24%	24%	20%	16%	19%	19%	19%	19%	19%
Operating Profit	39	39	41	54	62	60	60	64	147	166
OPM %	11%	11%	12%	10%	10%	11%	10%	10%	19%	20%
	2	2	5	20	8	10	12	21	13	12
Exceptional items			-9	23				10
Interest	35	35	13	13	0	0	0	0	0	0
Depreciation	34	34	32	35	34	32	26	23	26	26
Profit before tax	-28	-28	-8	49	36	38	45	72	134	152
				-27%	-12%	30%	36%	33%	23%	23%
Current tax							12	19	33
Deferred tax	3	3	2	-13	-4	11	4	5	-2
	-31	-31	-10	62	41	27	28	45	103	116
Profit to shareholders							27
YOY Profit Growth %					-34.07%	-34.76%	7.25%	59.04%	126.79%
EPS in Rs	-24.87	-24.87	-8.10	50.04	30.86	19.88	21.31	33.90	76.89	86.91

Compounded Sales Growth

5 Years:: 7%
3 Years:: 11%
TTM:: 21%

Compounded Profit Growth

5 Years:: 11%
3 Years:: 57%
TTM:: 116%

Stock Price CAGR

5 Years:: 67%
3 Years:: 82%
1 Year:: 262%

Return on Equity

4 Years:: 9%
Last Year:: 17%

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	355	355	302	341	515	575	538	575	639	769	810
YOY Sales Growth %			-14.99%	13.13%	50.71%	11.77%	-6.52%	6.98%	11.17%	20.22%
	312	312	268	301	468	506	476	514	569	625	648
Material Cost %	58%	58%	60%	51%	65%	65%	63%	61%	59%	50%	49%
Employee Cost %	8%	8%	10%	13%	7%	8%	10%	11%	11%	11%	11%
Other Expenses %	22%	22%	18%	24%	18%	15%	16%	17%	19%	20%	20%
Operating Profit	44	44	34	41	47	69	62	61	70	144	163
OPM %	12%	12%	11%	12%	9%	12%	11%	11%	11%	19%	20%
	1	1	5	5	18	8	10	11	21	11	11
Exceptional items			-9	-9	23				10
Interest	35	35	25	13	13
Depreciation	33	33	33	32	34	33	31	26	22	25	25
Profit before tax	-23	-23	-28	-8	41	45	40	47	79	131	149
					-32%	-10%	28%	35%	30%	24%	24%
Current tax								12	19	33
Deferred tax	3	3	-1	2	-13	-4	11	4	5	-2
	-27	-27	-27	-10	54	49	29	31	53	99	113
YOY Profit Growth %						-9.74%	-40.88%	5.32%	72.30%	88.98%
EPS in Rs	-21.54	-21.54	21.97	-8.10	43.97	37.12	24.67	22.82	39.32	74.29	84.65

Compounded Sales Growth

5 Years:: 8%
3 Years:: 13%
TTM:: 22%

Compounded Profit Growth

5 Years:: 13%
3 Years:: 51%
TTM:: 89%

Stock Price CAGR

5 Years:: 67%
3 Years:: 82%
1 Year:: 262%

Return on Equity

4 Years:: 9%
Last Year:: 17%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	13
Reserves	447	474	548	650
	42	41	2	12
Long term borrowings	39	39
Short term borrowings	4	3	2
	98	98	153	178
Trade payables	51	53	92	113
Current liabilities	83	79	136	162
Total Liabilities	601	627	716	854
	164	155	154	193
Gross block	433	387	383	417
Accumulated depreciation	270	232	230	224
Goodwill & intangibles	79	85	105	94
CWIP	67	22	29	55
	370	450	533	605
Inventories	120	122	100	129
Trade receivables	77	80	112	103
Cash & equivalents	21	49	58	25
Current assets	323	360	397	395
Total Assets	601	627	716	854

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	37	37	86	156
Profit for the year	27	28	45	103
Working capital changes	-25	-12	22	38
Direct taxes paid		-15	-15	-34
	-51	-7	-76	-182
Fixed assets purchased	-8	-14	-18	-38
Fixed assets sold		0	0	0
Investments purchased	-45		-65	-153
Investments sold	0	1	2	6
	-1	-1	-1	-3
Repayment of borrowings	-0	-1	-1	-2
Interest paid	-0	-0	-0	-1
Net Cash Flow	-15	29	9	-29
Free Cash Flow	29	24	68	118

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	5.8%	6.0%	8.6%	16.8%
ROCE	—	7.3%	8.2%	12.4%	19.4%
Operating margin	—	5.0%	5.6%	6.3%	14.5%
Net margin	—	4.8%	4.8%	7.0%	14.0%
Debt / equity	—	0.09	0.08	0.00	0.02
Current ratio	—	3.91	4.53	2.91	2.44

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities).

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 41.76%
FIIs 3.14%
DIIs 0.74%
Public 54.36%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%
	1.59%	1.48%	1.06%	1.18%	1.11%	1.34%	2.24%	1.86%	2.26%	2.80%	2.92%	3.14%
Foreign portfolio investors (Cat. I)	1.59%	1.48%	1.06%	1.18%	1.11%	1.34%	2.10%	1.86%	2.24%	2.47%	2.54%	2.44%
Foreign portfolio investors (Cat. II)							0.15%		0.01%	0.33%	0.38%	0.70%
	0.15%	0.15%	0.15%	0.15%			0.11%	0.75%	1.03%	1.20%	0.89%	0.74%
Alternative investment funds							0.11%	0.75%	1.03%	1.20%	0.89%	0.74%
	56.50%	56.61%	57.03%	56.91%	57.13%	56.90%	55.89%	55.63%	54.96%	54.24%	54.43%	54.36%
Retail (up to ₹2 lakh)	36.17%	37.13%	36.94%	36.50%	36.00%	35.60%	32.96%	31.03%	32.18%	31.23%	31.32%	31.87%
HNIs (above ₹2 lakh)	11.09%	9.76%	9.31%	8.81%	9.42%	11.21%	14.74%	14.27%	12.98%	13.17%	13.00%	12.15%
NRIs	2.46%	2.84%	3.56%	3.61%	3.85%	4.53%	1.86%	1.52%	1.51%	1.63%	1.60%	1.71%
Bodies corporate	3.16%	3.01%	3.07%	4.44%	4.29%	1.92%	2.67%	2.78%	2.14%	2.33%	2.98%	2.97%
IEPF	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%
No. of Shareholders	19,560	19,913	19,614	19,557	19,771	19,982	19,307	17,725	18,606	18,403	21,905	22,968

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Credit RatingVenus Remedies Limited vide its letter dated September 16, 2014 has informed the Exchange regarding the downgrading of external bank loan rating by CRISIL.16-Sep-2014

Concalls & investor meets

None filed recently.

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 7 Aug 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Questions about Venus Remedies Limited

What is the share price of Venus Remedies Limited today?

Venus Remedies Limited (VENUSREM) last traded at ₹1,650.70 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Venus Remedies Limited?

About ₹2,209 crore at the latest price.

What is the P/E ratio of Venus Remedies Limited?

About 19.0 times its earnings over the last 12 months.

Is Venus Remedies Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Venus Remedies Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Venus Remedies Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Venus Remedies Limited

Peer comparison

Quarterly Results

Profit & Loss

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Questions about Venus Remedies Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next